eGFRcrea GWAS and Prioritization
Kidney Epigenome and Transcriptome-based Multi-stage Prioritization for Kidney Disease
Bulk Download Links:
---------------------------------------------------
Summary statistics of eGFRcrea GWAS meta-analysis of 1.5 million individuals:
eGFRcrea_GWAS_S1.5million_Summary_Statistics.txt.gz
This table provides the summary statistics of eGFRcrea GWAS meta-analysis of 1.5 million individuals.
---------------------------------------------------
Significant eGFRcrea variants identified in this study:
eGFRcrea_GWAS_S1.5million_Significant_Variants.txt.gz
This table provides 90,950 significant variants associated with eGFRcrea by threshold of < 5e-8 and the validation based on eGFRcys and BUN.
---------------------------------------------------
Format:
MarkerName: RSID of variant
CHR: Chromosome (hg19) of variant
POS: Genome position (hg19) of variant
REF: Reference allele of variant based on dbSNP
ALT: Alternative allele of variant based on dbSNP
Freq_ALT: Frequency of alternative allele
MAF: Minor allele frequency
Zscore: Z score from meta-analysis, reported with respect to alternative allele
BETA: Effect size estimated from the z-statistics of the meta-analysis following a method proposed by Zhu et al. Nature Genetics (2016).
SE: Standard error of effect size, stimated from the z-statistics of the meta-analysis following a method proposed by Zhu et al. Nature Genetics (2016).
P.value: P value from meta-analysis
N: Sample size
Direction: Direction of effect size in each study, reported with respect to alternative allele
HetISq, HetChiSq, HetDf, HetPVal: heterogeneity statistics from METAL